drugset
drugset / Trial / NCT03420222

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

NCT03420222 ↗

Phase 2 Terminated 10 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate AVP-786 for the treatment of Intermittent Explosive Disorder (IED).

Timeline

Start
2018-01-18
Primary completion
2018-12-28
Completion
2018-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Deudextromethorphan Unknown 42.63 mg Oral
Subject Quinidine Small molecule 4.9 mg Oral

Indications

intermittent explosive disorder